uniQure NV (QURE)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about uniQure NV (QURE)
Company Performance

Current Price

as of Oct 18, 2024

$6.42

P/E Ratio

N/A

Market Cap

$312.64M

Description

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Metrics

Overview

  • HQAmsterdam, NH
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerQURE
  • Price$6.42+2.23%

Trading Information

  • Market Cap$312.64M
  • Float92.44%
  • Average Daily Volume (1m)842,355
  • Average Daily Volume (3m)717,162
  • EPS-$5.92

Company

  • Revenue$27.71M
  • Rev Growth (1yr)359.37%
  • Net Income-$56.30M
  • Gross Margin8.94%
  • EBITDA Margin-402.00%
  • EBITDA-$44.73M
  • EV$227.84M
  • EV/Revenue8.22
  • P/EN/A
  • P/S11.27
  • P/B3.22
Documents
SEC Filings
8-K (2024-10-15)
8-K (2024-09-23)
8-K (2024-08-15)
8-K (2024-08-01)
8-K (2024-07-23)
8-K (2024-07-09)
8-K (2024-07-01)
8-K (2024-06-20)
8-K (2024-06-03)
8-K (2024-05-07)
8-K (2024-04-12)
8-K (2024-02-28)
8-K (2023-12-19)
8-K (2023-11-17)
8-K (2023-11-07)
8-K (2023-10-05)
8-K (2023-08-01)
8-K (2023-06-22)
8-K (2023-06-16)
8-K (2023-05-16)
8-K (2023-05-09)
8-K (2023-04-05)
8-K (2023-02-27)
8-K (2023-02-21)
8-K (2023-01-31)
10-Q (2024-08-01)
10-Q (2024-05-07)
10-Q (2023-11-07)
10-Q (2023-08-01)
10-Q (2023-05-09)
10-K (2024-02-28)
10-K (2023-02-27)
Factset Street Account
uniQure provides update on phase I/II trials of AMT-130 for the treatment of Huntington's disease; call at 8:30ET ($7.98, 0.00) (2023-12-19T12:12:03Z)
uniQure NV reports Q3 EPS ($1.88) vs year-ago ($1.02) ($6.11, 0.00) (2023-11-07T12:09:25Z)
uniQure NV downgraded to neutral from buy at Mizuho Securities USA ($7.99, 0.00) (2023-12-18T21:14:58Z)
uniQure announces strategic reorganization to reduce operating expenses and support advancement of multiple clinical-stage programs ($6.03, 0.00) (2023-10-05T11:09:25Z)
uniQure announces FDA clearance of IND application for AMT-191 gene therapy for Fabry disease ($6.98, 0.00) (2023-11-29T12:08:49Z)
CSL announces Health Canada authorizes HEMGENIX (etranacogene dezaparvovec) as first gene therapy for hemophilia B (A$234.34, 0.00) (2023-10-26T19:06:39Z)
Earnings Calls
Earnings Report 2015Q3
Earnings Report (2015-11-30)
Factset
Factset Business Description